Intestinal failure-associated liver disease (IFALD) is a feared and potentially fatal complication in newborns receiving long-term total parenteral nutrition (TPN) (TPN). The purpose of this study is to look into the influence of exogenous secretin on liver pathology and function in a rat model of PN-associated liver disease (PNALD). Male Sprague-Dawley rats were catheterized in the right jugular vein to undergo 14 days of continuous TPN treatment. All rats were divided into three groups: the Control group, which received no surgery or TPN and was fed standard rat chow ad libitum; the TPN group, which received catheter insertion and TPN treatment; and the TPN/S group, which received catheter insertion, TPN treatment, and exogenous secretin treatment on a daily basis. We retrieved the animals’ liver and blood samples for additional testing 14 days following the original operation. In comparison to the TPN group, the TPN/S group exhibited lower levels of direct bilirubin and total bile acid in the liver, as well as better histology results. Exogenous secretin also boosted the canalicular transporter while inhibiting the basolateral transporter of bile acid in the liver.

Secretin may ameliorate cholestasis in this PNALD animal model by increasing canalicular transport, reducing basolateral export of hepatic bile acid, and finally decreasing total bile acid levels in the liver.